‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study
Morgan Ballard(Stanford University), Kimberly H. Allison(Stanford University), Mara H. Rendi(University of Washington), Florencia G. Jalikis(University of Washington Medical Center), Robert B. West(Stanford University), Yunn‐Yi Chen(University of Vermont), Megan L. Troxell(Stanford University), Gregor Krings(Cleveland Clinic), Rodney A. Schmidt(University of Washington Medical Center), Suzanne M. Dintzis(University of Washington Medical Center), Richard K. Sibley(Stanford University), Kristin C. Jensen(Shaanxi Research Association for Women and Family)
Cited by 102
Related Papers
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
|Cell|2018|1.2k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k